Blog
New
Designing NIPT Assays: Coverage, Bias, and the Cost of False Positives
Designing NIPT Assays: Coverage, Bias, and the Cost of False Positives
Barkha Pradhan
5 Min Read
Share
The Growing Complexity of NIPT Assay Design
Non-invasive prenatal testing (NIPT) has changed the way prenatal screening is performed. By analysing cell-free DNA (cfDNA) from a maternal blood sample, NIPT can screen for selected chromosomal abnormalities without requiring an invasive procedure.
But as NIPT expands beyond a small number of well-established targets, assay design becomes increasingly challenging.
More targets mean more regions to cover, more opportunities for amplification bias, and more variables that can affect the reliability of the final result. And in prenatal screening, even a small number of false-positive results can have significant consequences for patients and clinicians.
So, what makes designing a scalable NIPT assay difficult? and how can a better assay-development strategy help?
The challenge starts with coverage
A typical NIPT sample contains a mixture of cfDNA originating from both the mother and the fetus. The fetal fraction can be relatively small, which means the signal being measured may already be subtle.
Now consider an assay designed to look at multiple genomic targets simultaneously.
The assay needs to generate reliable signals across those targets, ideally with consistent performance from one target to another and across different samples. If some regions are preferentially amplified while others are underrepresented, the resulting data can become uneven.
This is where coverage and amplification bias become important.
An assay may technically detect a target, but if different targets behave very differently during amplification, interpreting the data becomes more complicated.
More targets, more complexity
The obvious solution is multiplexing: test multiple targets in the same reaction.
But multiplexing is not simply a matter of adding more primers.
Each additional target introduces another set of considerations:
Will all targets amplify efficiently under the same conditions?
Will some targets dominate the reaction?
Will primer interactions affect performance?
Can the assay maintain sufficient coverage across all regions?
Can the design scale when additional targets or indications are introduced?
Can the same workflow be maintained as the assay evolves?
These challenges become particularly important when an NIPT platform is expected to move beyond a limited number of screening targets.
Why bias matters
PCR amplification is not always perfectly uniform.
Differences in sequence composition, target characteristics and amplification efficiency can cause some regions to be represented more strongly than others. In a multiplex assay, these differences can accumulate.
The result is amplification bias; an uneven representation of the targets being measured.
For NIPT, this matters because the final interpretation depends on detecting relatively small differences in the representation of genomic material.
A robust assay therefore needs more than high analytical sensitivity for individual targets. It needs a design that supports consistent and predictable performance across the panel.
The real cost of a false positive
In many diagnostic settings, a false positive is undesirable.
In prenatal screening, the impact can be particularly significant.
NIPT is a screening test, not a diagnostic test. A positive screening result generally requires follow-up testing to confirm whether the suspected abnormality is actually present.
A false-positive result can therefore lead to additional testing, clinical consultations, anxiety and uncertainty for the expecting family.
This makes assay design more than a technical exercise. The quality of the assay directly affects the reliability of the information clinicians and patients receive.
Scaling NIPT without reinventing the assay each time
This creates an important question for assay developers:
How do you increase the number of targets without increasing assay complexity at the same rate?
At AlgoBio, our approach to assay development is built around creating assay architectures that can be adapted across applications rather than treating every new target as an entirely separate assay-development problem.
Our sequence-transduction-based approach provides a way to work with multiple targets within a common amplification framework. Universal primer-based amplification can help provide a consistent downstream PCR strategy while allowing target-specific sequence information to be incorporated upstream.
In practical terms, this means that once the underlying amplification workflow is established, adding or adapting targets does not necessarily require building a completely different PCR setup from scratch.
That can be valuable when developing larger or evolving NIPT panels.
From one assay to multiple targets
Think of it as building a common foundation rather than constructing a new building for every target.
The target-recognition component can be designed for the genomic region of interest, while the downstream amplification can use a common framework.
This creates an opportunity to:
Expand target coverage → support multiplexing → maintain a common workflow → reduce development complexity.
Of course, multiplexing still requires careful optimisation and validation. Universal primers do not automatically solve every multiplexing challenge. Target-specific performance, interactions, coverage and analytical validation remain critical.
The advantage is that the assay-development process can be designed with scalability in mind from the beginning.
Why this matters for the future of NIPT
The future of NIPT is likely to involve increasingly informative panels and applications. As the number of targets grows, assay developers will need approaches that can balance:
Coverage + consistency + scalability + cost + turnaround time.
A platform that requires a completely new amplification strategy every time a target is added can become increasingly difficult and expensive to scale.
A common assay framework, on the other hand, can make it easier to extend the same underlying technology to new targets and applications.
At AlgoBio, we are working toward making assay development more modular, scalable and adaptable, helping translate complex sequence-level detection into practical diagnostic workflows.
Because the goal is not simply to detect more targets.
It is to build assays that can scale with the questions diagnostics need to answer.
The Growing Complexity of NIPT Assay Design
Non-invasive prenatal testing (NIPT) has changed the way prenatal screening is performed. By analysing cell-free DNA (cfDNA) from a maternal blood sample, NIPT can screen for selected chromosomal abnormalities without requiring an invasive procedure.
But as NIPT expands beyond a small number of well-established targets, assay design becomes increasingly challenging.
More targets mean more regions to cover, more opportunities for amplification bias, and more variables that can affect the reliability of the final result. And in prenatal screening, even a small number of false-positive results can have significant consequences for patients and clinicians.
So, what makes designing a scalable NIPT assay difficult? and how can a better assay-development strategy help?
The challenge starts with coverage
A typical NIPT sample contains a mixture of cfDNA originating from both the mother and the fetus. The fetal fraction can be relatively small, which means the signal being measured may already be subtle.
Now consider an assay designed to look at multiple genomic targets simultaneously.
The assay needs to generate reliable signals across those targets, ideally with consistent performance from one target to another and across different samples. If some regions are preferentially amplified while others are underrepresented, the resulting data can become uneven.
This is where coverage and amplification bias become important.
An assay may technically detect a target, but if different targets behave very differently during amplification, interpreting the data becomes more complicated.
More targets, more complexity
The obvious solution is multiplexing: test multiple targets in the same reaction.
But multiplexing is not simply a matter of adding more primers.
Each additional target introduces another set of considerations:
Will all targets amplify efficiently under the same conditions?
Will some targets dominate the reaction?
Will primer interactions affect performance?
Can the assay maintain sufficient coverage across all regions?
Can the design scale when additional targets or indications are introduced?
Can the same workflow be maintained as the assay evolves?
These challenges become particularly important when an NIPT platform is expected to move beyond a limited number of screening targets.
Why bias matters
PCR amplification is not always perfectly uniform.
Differences in sequence composition, target characteristics and amplification efficiency can cause some regions to be represented more strongly than others. In a multiplex assay, these differences can accumulate.
The result is amplification bias; an uneven representation of the targets being measured.
For NIPT, this matters because the final interpretation depends on detecting relatively small differences in the representation of genomic material.
A robust assay therefore needs more than high analytical sensitivity for individual targets. It needs a design that supports consistent and predictable performance across the panel.
The real cost of a false positive
In many diagnostic settings, a false positive is undesirable.
In prenatal screening, the impact can be particularly significant.
NIPT is a screening test, not a diagnostic test. A positive screening result generally requires follow-up testing to confirm whether the suspected abnormality is actually present.
A false-positive result can therefore lead to additional testing, clinical consultations, anxiety and uncertainty for the expecting family.
This makes assay design more than a technical exercise. The quality of the assay directly affects the reliability of the information clinicians and patients receive.
Scaling NIPT without reinventing the assay each time
This creates an important question for assay developers:
How do you increase the number of targets without increasing assay complexity at the same rate?
At AlgoBio, our approach to assay development is built around creating assay architectures that can be adapted across applications rather than treating every new target as an entirely separate assay-development problem.
Our sequence-transduction-based approach provides a way to work with multiple targets within a common amplification framework. Universal primer-based amplification can help provide a consistent downstream PCR strategy while allowing target-specific sequence information to be incorporated upstream.
In practical terms, this means that once the underlying amplification workflow is established, adding or adapting targets does not necessarily require building a completely different PCR setup from scratch.
That can be valuable when developing larger or evolving NIPT panels.
From one assay to multiple targets
Think of it as building a common foundation rather than constructing a new building for every target.
The target-recognition component can be designed for the genomic region of interest, while the downstream amplification can use a common framework.
This creates an opportunity to:
Expand target coverage → support multiplexing → maintain a common workflow → reduce development complexity.
Of course, multiplexing still requires careful optimisation and validation. Universal primers do not automatically solve every multiplexing challenge. Target-specific performance, interactions, coverage and analytical validation remain critical.
The advantage is that the assay-development process can be designed with scalability in mind from the beginning.
Why this matters for the future of NIPT
The future of NIPT is likely to involve increasingly informative panels and applications. As the number of targets grows, assay developers will need approaches that can balance:
Coverage + consistency + scalability + cost + turnaround time.
A platform that requires a completely new amplification strategy every time a target is added can become increasingly difficult and expensive to scale.
A common assay framework, on the other hand, can make it easier to extend the same underlying technology to new targets and applications.
At AlgoBio, we are working toward making assay development more modular, scalable and adaptable, helping translate complex sequence-level detection into practical diagnostic workflows.
Because the goal is not simply to detect more targets.
It is to build assays that can scale with the questions diagnostics need to answer.
The Growing Complexity of NIPT Assay Design
Non-invasive prenatal testing (NIPT) has changed the way prenatal screening is performed. By analysing cell-free DNA (cfDNA) from a maternal blood sample, NIPT can screen for selected chromosomal abnormalities without requiring an invasive procedure.
But as NIPT expands beyond a small number of well-established targets, assay design becomes increasingly challenging.
More targets mean more regions to cover, more opportunities for amplification bias, and more variables that can affect the reliability of the final result. And in prenatal screening, even a small number of false-positive results can have significant consequences for patients and clinicians.
So, what makes designing a scalable NIPT assay difficult? and how can a better assay-development strategy help?
The challenge starts with coverage
A typical NIPT sample contains a mixture of cfDNA originating from both the mother and the fetus. The fetal fraction can be relatively small, which means the signal being measured may already be subtle.
Now consider an assay designed to look at multiple genomic targets simultaneously.
The assay needs to generate reliable signals across those targets, ideally with consistent performance from one target to another and across different samples. If some regions are preferentially amplified while others are underrepresented, the resulting data can become uneven.
This is where coverage and amplification bias become important.
An assay may technically detect a target, but if different targets behave very differently during amplification, interpreting the data becomes more complicated.
More targets, more complexity
The obvious solution is multiplexing: test multiple targets in the same reaction.
But multiplexing is not simply a matter of adding more primers.
Each additional target introduces another set of considerations:
Will all targets amplify efficiently under the same conditions?
Will some targets dominate the reaction?
Will primer interactions affect performance?
Can the assay maintain sufficient coverage across all regions?
Can the design scale when additional targets or indications are introduced?
Can the same workflow be maintained as the assay evolves?
These challenges become particularly important when an NIPT platform is expected to move beyond a limited number of screening targets.
Why bias matters
PCR amplification is not always perfectly uniform.
Differences in sequence composition, target characteristics and amplification efficiency can cause some regions to be represented more strongly than others. In a multiplex assay, these differences can accumulate.
The result is amplification bias; an uneven representation of the targets being measured.
For NIPT, this matters because the final interpretation depends on detecting relatively small differences in the representation of genomic material.
A robust assay therefore needs more than high analytical sensitivity for individual targets. It needs a design that supports consistent and predictable performance across the panel.
The real cost of a false positive
In many diagnostic settings, a false positive is undesirable.
In prenatal screening, the impact can be particularly significant.
NIPT is a screening test, not a diagnostic test. A positive screening result generally requires follow-up testing to confirm whether the suspected abnormality is actually present.
A false-positive result can therefore lead to additional testing, clinical consultations, anxiety and uncertainty for the expecting family.
This makes assay design more than a technical exercise. The quality of the assay directly affects the reliability of the information clinicians and patients receive.
Scaling NIPT without reinventing the assay each time
This creates an important question for assay developers:
How do you increase the number of targets without increasing assay complexity at the same rate?
At AlgoBio, our approach to assay development is built around creating assay architectures that can be adapted across applications rather than treating every new target as an entirely separate assay-development problem.
Our sequence-transduction-based approach provides a way to work with multiple targets within a common amplification framework. Universal primer-based amplification can help provide a consistent downstream PCR strategy while allowing target-specific sequence information to be incorporated upstream.
In practical terms, this means that once the underlying amplification workflow is established, adding or adapting targets does not necessarily require building a completely different PCR setup from scratch.
That can be valuable when developing larger or evolving NIPT panels.
From one assay to multiple targets
Think of it as building a common foundation rather than constructing a new building for every target.
The target-recognition component can be designed for the genomic region of interest, while the downstream amplification can use a common framework.
This creates an opportunity to:
Expand target coverage → support multiplexing → maintain a common workflow → reduce development complexity.
Of course, multiplexing still requires careful optimisation and validation. Universal primers do not automatically solve every multiplexing challenge. Target-specific performance, interactions, coverage and analytical validation remain critical.
The advantage is that the assay-development process can be designed with scalability in mind from the beginning.
Why this matters for the future of NIPT
The future of NIPT is likely to involve increasingly informative panels and applications. As the number of targets grows, assay developers will need approaches that can balance:
Coverage + consistency + scalability + cost + turnaround time.
A platform that requires a completely new amplification strategy every time a target is added can become increasingly difficult and expensive to scale.
A common assay framework, on the other hand, can make it easier to extend the same underlying technology to new targets and applications.
At AlgoBio, we are working toward making assay development more modular, scalable and adaptable, helping translate complex sequence-level detection into practical diagnostic workflows.
Because the goal is not simply to detect more targets.
It is to build assays that can scale with the questions diagnostics need to answer.